124
Participants
Start Date
January 3, 2024
Primary Completion Date
July 9, 2025
Study Completion Date
July 3, 2028
ALXN1850
ALXN1850 will be administered via subcutaneous (SC) injection.
Placebo
Placebo will be administered via SC injection.
Research Site, Taipei
Research Site, Taoyuan District
Research Site, St Leonards
Research Site, Parkville
Research Site, Clayton
Research Site, Herston
Research Site, Berlin
Research Site, Garden City
Research Site, Suwon
Research Site, Granada
Research Site, Milan
Research Site, Milan
Research Site, Hamburg
Research Site, Erzurum
Research Site, Durham
Research Site, Madrid
Research Site, Padua
Research Site, Verona
Research Site, Nashville
Research Site, San Cristóbal de La Laguna
Research Site, Santander
Research Site, Columbus
Research Site, Indianapolis
Research Site, Florence
Research Site, Ramat Gan
Research Site, Bonn
Research Site, Pisa
Research Site, San Giovanni Rotondo
Research Site, Paris
Research Site, Bad Reichenhall
Research Site, Poitiers
Research Site, Würzburg
Research Site, Beijing
Research Site, Beijing
Research Site, Shanghai
Research Site, Qingdao
Research Site, Nanchang
Research Site, Changsha
Research Site, Shenzhen
Research Site, Chengdu
Research Site, Ashkelon
Research Site, Ciudad de Buenos Aires
Research Site, Belo Horizonte
Research Site, Brasília
Research Site, Recife
Research Site, Salvador
Research Site, São Paulo
Research Site, São Paulo
Research Site, Calgary
Research Site, Edmonton
Research Site, Winnepeg
Research Site, Oakville
Research Site, Trois-Rivières
Research Site, Hiroshima
Research Site, Iizuka-shi
Research Site, Osaka
Research Site, Sapporo
Research Site, Yaizu-shi
Research Site, Lodz
Research Site, Seoul
Research Site, Seoul
Research Site, Barcelona
Research Site, Vitoria-Gasteiz
Research Site, Ankara
Research Site, London
Lead Sponsor
Alexion Pharmaceuticals, Inc.
INDUSTRY